Rama Nuno, Monteiro Alexandre, Bernardo João E, Eugénio Luís, Antunes Manuel J
Cardiothoracic Surgery, University Hospital, 3000-075 Coimbra, Portugal.
Eur J Cardiothorac Surg. 2009 Mar;35(3):444-9. doi: 10.1016/j.ejcts.2008.10.047. Epub 2009 Jan 10.
To analyse our experience with excision of lung metastases from colorectal carcinoma (CRC), and to evaluate clinically relevant prognostic factors, identifying the cluster of patients who would benefit from this procedure.
Sixty-one patients, 42 men (69%), with primary CRC who underwent 94 curative resections of pulmonary metastases were retrospectively reviewed. Age was 30-80 years (mean 61.2+/-15). Population was analysed for age, sex, disease-free interval (DFI), prethoracotomy carcinoembryonic antigen (CEA) level, location and histology of primary tumour, number of lung lesions (and size of largest resected metastasis), type of lung resection, nodal involvement (hilar/mediastinal), use of adjuvant treatment, morbid-mortality and immediate and follow-up survival.
Mean DFI was 29+/-22 months (range 5-132 months). There was no hospital mortality and significant morbidity occurred in five patients (8.2%). Mean follow-up was 39+/-4 months (range 4-173 months). Mean overall survival and disease-free survival were 67+/-16 months and 52+/-6 months, respectively. Three-, 5- and 10-year survival rates from date of primary colorectal resection were 83%, 71% and 43%, respectively. Three-, 5- and 10-year survival rates from date of lung resection were 61%, 48% and 11%, respectively. Five-year survival was 57% in patients with normal prethoracotomy CEA levels and 18% for those with high levels (>5 ng/ml) (p=0.039).
Pulmonary metastasectomy has potential survival benefit for patients with metastatic colorectal carcinoma. Low morbidity and mortality rates, contrasting with lack of any other effective therapy, justify aggressive surgical management. Single deposits, DFI >36 months and normal prethoracotomy serum CEA were significant independent prognostic factors.
分析我们对结直肠癌(CRC)肺转移灶切除的经验,并评估临床相关的预后因素,确定能从该手术中获益的患者群体。
对61例原发性CRC患者(42例男性,占69%)进行回顾性分析,这些患者接受了94次肺转移瘤的根治性切除。年龄为30 - 80岁(平均61.2±15岁)。分析患者的年龄、性别、无病间期(DFI)、开胸术前癌胚抗原(CEA)水平、原发肿瘤的位置和组织学类型、肺内病变数量(及最大切除转移灶的大小)、肺切除类型、淋巴结受累情况(肺门/纵隔)、辅助治疗的使用、病残率和死亡率以及近期和随访生存率。
平均DFI为29±22个月(范围5 - 132个月)。无医院死亡病例,5例患者(8.2%)发生了严重并发症。平均随访时间为39±4个月(范围4 - 173个月)。平均总生存期和无病生存期分别为67±16个月和52±6个月。从原发性结直肠癌切除日期起的3年、5年和10年生存率分别为83%、71%和43%。从肺切除日期起的3年、5年和10年生存率分别为61%、48%和11%。开胸术前CEA水平正常的患者5年生存率为57%,高水平(>5 ng/ml)患者为18%(p = 0.039)。
肺转移瘤切除术对转移性结直肠癌患者有潜在的生存益处。与缺乏其他有效治疗方法相比,低病残率和死亡率证明积极的手术治疗是合理的。单个转移灶、DFI>36个月和开胸术前血清CEA正常是重要的独立预后因素。